You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞通窝轮》【瑞通认股证牛熊证】石药八日累挫18%考验百天线 银娱上试10及50天线 石药购27547 熊63134/ 银河购24070 沽12901/ 吉利牛64261 熊62744
阿思达克 12-10 10:25

市场观望今周欧美议息、英国大选、中美贸易谈判等多项重要经济及政治事件发展,道指隔晚收报27909点,跌105点(或0.4%)。

恒指昨好淡争持,收报26494点,跌3点。今早曾跌逾100点,其後於26400点附近整固。恒指好仓(牛证及认购权证)昨净流入48万港元(下同),恒指淡仓(熊证及认沽权证)同日净流入逾2800万元,反映较多投资者看淡港股後市。昨日恒指牛证街货重货区为收回价25900至25999点,而熊证街货重货区为收回价27000至27099点。

市传内地第三轮药品集采规则流出,有券商估计今轮集采中标价仍会明显降价,医药股昨继续捱沽。石药(01093)昨挫逾半成,险守17元收市,是表现最差蓝筹,盘中最多跌6.2%至16.82元,回至十月时水平。石药於11月29日裂口下跌,八个交易日最多累跌达18%。股份今早跌势持续,曾下试16.7元水平,留意下方100天线(约16.5元)的支持力度。昨分别有260万元和43万元净流入其好仓和淡仓。

有券商指中央对内房行业释出正面讯号,料会放松房策,带动内房股昨受资金追捧。碧桂园(02007)昨曾升抵一个月高位11.56元,其後升势回顺,收升1.6%於11.32元,企於各平均线之上。今早大致靠稳,於11.4元之下徘徊。昨分别有近140万元和1万元净流入其好仓和淡仓。

银娱(00027)日前录大手成交,但昨日股价波幅不大,大致於52元附近窄幅上落。银娱今早变动不大,在52元附近徘徊,逐步企稳10及50天线(同於52元)。昨有56万元净流入其好仓,淡仓同日亦有近210万元净流入。

友邦(01299)是昨日最多北水经港股通净流出的股份,单日净流出1.68亿元。股份昨续於20天(78.4元)和50天线(77.2元)区间内上落,收报77.6元,今早於77元上落。昨分别有17万元和11万元净流入其好仓和淡仓。

瑞通相关认股证之选择:

石药贴价、中短期购27547,行使价:17.38元,2020年4月到期,实际杠杆:4.9倍

石药轻微价外、中年期沽28344,行使价:14.68元,2020年7月到期,实际杠杆:3.4倍

碧桂轻微价外、短期购18754,行使价:12.12元,2020年2月到期,实际杠杆:8倍

银河轻微价外、中短期购24070,行使价:58.8元,2020年4月到期,实际杠杆:8.3倍

银河贴价、中短期沽12901,行使价:51.8元,2020年6月到期,实际杠杆:4.2倍

友邦贴价、中短期购13595,行使价:79.95元,2020年3月到期,实际杠杆:9.8倍

友邦贴价、中短期沽13262,行使价:75元,2020年6月到期,实际杠杆:6.3倍

阿里轻微价外、中短期购13507,行使价:208元,2020年5月到期,实际杠杆:5.9倍

瑞通相关牛熊证之选择:

恒指N类牛证58812,收回价及行使价:25820点,杠杆比率:37.3倍

恒指熊证63720,收回价:26990点,杠杆比率:36.7倍

石药牛证63136,收回价:16.2元,杠杆比率:10.3倍

石药熊证63134,收回价:19.3元,杠杆比率:5.3倍

银河牛证61488,收回价:48.6元,杠杆比率:10倍

银河熊证60495,收回价:55.5元,杠杆比率:10.6倍

友邦牛证62682,收回价:73.6元,杠杆比率:14.6倍

友邦熊证62466,收回价:80.8元,杠杆比率:18.9倍

美团牛证62230,收回价:97.51元,杠杆比率:12.4倍

美团熊证62736,收回价:105.7元,杠杆比率:11.3倍

吉利牛证64261,收回价:13.9元,杠杆比率:8.4倍

吉利熊证62744,收回价:15.9元,杠杆比率:8.4倍重要风险通知

本结构性产品并无抵押品。

结构性产品之价格一般可急升亦可急跌,有可能损失结构性产品之全部或重大部分购买价,阁下对此应有所准备。

阁下投资前应了解产品风险,如有需要应谘询专业建议。~重要声明:

以上资讯由第三方提供,AASTOCKS.com Limited对於任何包含於、经由、连结、下载或从任何与本网站有关服务所获得之资讯、内容或广告,不声明或保证其内容之正确性或可靠性。对於您透过本网站上之广告、资讯或要约而展示、购买或取得之任何产品、资讯资料,本公司亦不负品质保证之责任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account